newsfilter
← Latest News
Business Wire·

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Enrollment Completed for Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss; Readout Expected in Q1 2023 Company on Track for Q4 Clinical Trial Start of its Second Hearing Restoration Program,